Scientific article

Safety and efficacy of once-daily nevirapine dosing: a multicohort study

Published inAntiviral therapy, vol. 14, no. 7, p. 931-938
Publication date2009

BACKGROUND: Nevirapine (NVP) is often prescribed once daily in clinical practice in combination with a once daily nucleoside backbone. We investigated the relationship of NVP dosing with safety and efficacy. METHODS: Patients from the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort study, Canadian HAART Observational Medical Evaluation and Research (HOMER) cohort and Swiss HIV Cohort Study (SHCS) using NVP-based combination therapy either once daily or twice daily were included. Risk factors for discontinuing NVP because of hypersensitivity reactions (HSRs) were investigated using multivariate logistic regression. Risk factors for virological failure 96 weeks after NVP initiation were identified using logistic regression and Cox models. RESULTS: Of 5,636 patients (774 once daily and 4,862 twice daily), 268 (4.8%) discontinued NVP because of HSR between 2 and 18 weeks. Logistic regression showed that, compared with patients with detectable HIV type-1 (HIV-1) RNA starting twice-daily NVP, there was a significantly higher risk of discontinuation of once-daily NVP because of HSR in patients with detectable HIV-1 RNA at the start of NVP (odds ratio [OR] 1.52; P=0.04), whereas the risk was actually significantly lower in patients starting once-daily NVP with undetectable HIV-1 RNA (OR 0.44; P=0.04). Cox models showed that risk of virological failure was not different for twice- versus once-daily NVP in treatment-naive patients (twice-daily versus once-daily hazard ratio [HR] 1.01; P=0.95), treatment-experienced patients experiencing treatment failure (twice-daily versus once-daily HR 1.22; P=0.30) or patients with undetectable HIV-1 RNA simplifying treatment with NVP (twice-daily versus once-daily HR 1.29; P=0.30). CONCLUSIONS: Initiation of a once-daily NVP-based regimen in patients with suppressed viraemia carries a low risk of treatment-limiting HSR. Once- or twice-daily NVP-based regimens appear to have similar antiretroviral efficacy.

  • Adenine/analogs & derivatives/therapeutic use
  • Adult
  • Anti-HIV Agents/administration & dosage/adverse effects
  • Cohort Studies
  • Drug Administration Schedule
  • Drug Hypersensitivity/etiology
  • Drug Therapy, Combination
  • Female
  • HIV Infections/ drug therapy
  • HIV-1/drug effects
  • Humans
  • Male
  • Middle Aged
  • Nevirapine/administration & dosage/adverse effects
  • Phosphonic Acids/therapeutic use
  • Retrospective Studies
  • Treatment Outcome
Research group
Citation (ISO format)
CALMY, Alexandra et al. Safety and efficacy of once-daily nevirapine dosing: a multicohort study. In: Antiviral therapy, 2009, vol. 14, n° 7, p. 931–938. doi: 10.3851/IMP1418
ISSN of the journal1359-6535

Technical informations

Creation07/12/2010 2:36:43 PM
First validation07/12/2010 2:36:43 PM
Update time03/14/2023 3:54:15 PM
Status update03/14/2023 3:54:15 PM
Last indexation05/02/2024 11:41:01 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack